Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | VEGFA | P15692 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155271 | 0.90 | NPC1 (0.55) | NPC1RAB9AMAPTMAPK1MRGPRX4 | |
| SCHEMBL5741190 | 0.88 | NPC1 (0.62) | NPC1RAB9AMAPTMAPK1TDP1 | |
| SCHEMBL1154249 | 0.86 | NPC1 (0.70) | NPC1RAB9AMAPTL3MBTL1MRGPRX4 | |
| SCHEMBL1154971 | 0.86 | NPC1 (0.51) | NPC1RAB9AKDM1AMRGPRX4MAPK14 | |
| SCHEMBL1155280 | 0.86 | NPC1 (0.51) | NPC1RAB9AMRGPRX4MAOBMAPK14 | |
| SCHEMBL1154479 | 0.86 | NPC1 (0.55) | NPC1RAB9AKDM1AMAPTMAPK1 | |
| SCHEMBL1154507 | 0.86 | MAPK14 (0.54) | NPC1RAB9AL3MBTL1MRGPRX4MAOB | |
| SCHEMBL1154474 | 0.84 | CYP11B1 (0.43) | NPC1RAB9AMAPTL3MBTL1MRGPRX4 | |
| SCHEMBL1154530 | 0.84 | MAPK14 (0.46) | NPC1RAB9AKDM1AMAPTMAPK1 | |
| SCHEMBL1154287 | 0.84 | MCL1 (0.55) | NPC1RAB9AMAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0624567-B1 | Derivatives of 3-fluorophenol, process for their preparation and their use | CLARIANT GMBH (DE) | 1999-12-08 | — | — | EP | claimed |
| EP-0624567-A2 | Derivatives of 3-fluorophenol, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-17 | — | — | EP | claimed |
| EP-3750890-B1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | SHIJIAZHUANG YILING PHARMACEUTICAL CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| US-11396504-B2 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | FUDAN UNIVERSITY (CN) | 2022-07-26 | — | — | US | disclosed |
| CN-110117278-B | Alkoxybenzo five-membered (six-membered) heterocyclic amine compound and pharmaceutical application thereof | 石家庄以岭药业股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-20210032230-A1 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | disclosed |
| US-20210032230-A1 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-3750890-A1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Fudan University (CN) | 2020-12-16 | — | — | EP | disclosed |
| EP-3750890-A1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Fudan University (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154047-A1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 复旦大学 | 2019-08-15 | — | — | WO | disclosed |
| EP-3121176-A1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2017-01-25 | — | — | EP | disclosed |
| US-7888366-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1963294-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| EP-1765810-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Decode Chemistry, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123724-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | US | disclosed |
| EP-0624567-B1 | Derivatives of 3-fluorophenol, process for their preparation and their use | CLARIANT GMBH (DE) | 1999-12-08 | — | — | EP | disclosed |
| EP-0624567-A2 | Derivatives of 3-fluorophenol, process for their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | SMN1; SMN2, MUSK, MYO3B | NPC1 4388/4885RAB9A 1250/4885KDM1A 508/4885 |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | NPC1 3005/4885RAB9A 3137/4885KDM1A 2902/4885 |
| US-20210032230-A1 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | LIPC, GPR119, VIP | NPC1 436/4885RAB9A 2012/4885KDM1A 1871/4885 |
| US-11396504-B2 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | LIPC, GPR119, VIP | NPC1 436/4885RAB9A 2012/4885KDM1A 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.